LIANY.US LianBio
- Market cap
- USD 5.35M
- P/E
- -
- P/B
- 0.03x
- ROE
- 23.9%
- Dividend yield
- 886.05%
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Sep 2025.
Is LIANY.US undervalued?
Graham numberThe Graham number of LianBio cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
LianBio fundamental analysis
No fundamental analysis for LianBio yet.
LianBio stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About LianBio
LianBio, operates as a biotechnology company in China and other Asian countries. It offers medicines for cardiovascular, oncology, ophthalmology, and inflammatory disease indications. The company develops mavacamten for the treatment of obstructive hypertrophic cardiomyopathy, which is in Phase 3 EXPLORER-CN trial; TP-03 for the treatment of Demodex blepharitis and meibomian gland disease, which is in Phase 3 LIBRA trial; NBTXR3 for the treatment of head and neck squamous ce…
Full company profileLianBio financial statements
LianBio annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | - | 0.00 | 0.00 | 0.00 | - | - | - |
| Gross Profit | - | -76.1K | -526K | -1.01M | -1.33M | -801K | - |
| Operating Income | -24.4M | -135M | -196M | -125M | -99.5M | -38.9M | -1.27M |
| EBITDA | -24.4M | -135M | -196M | -109M | 313M | 3.26M | -1.27M |
| Net Income | -24.4M | -140M | -197M | -110M | 311M | 2.48M | 4.91M |
| EPS | -0.23 | -1.33 | -1.83 | -1.02 | 2.87 | 0.02 | 0.05 |
| Balance Sheet | |||||||
| Total Assets | 43.9M | 279M | 426M | 320M | 618M | 63.7M | 20.5M |
| Total Liabilities | 3.69M | 27.6M | 39.0M | 26.3M | 36.8M | 859K | 14.0K |
| Shareholders' Equity | 39.2M | 217M | 354M | 260M | 581M | 62.9M | 20.5M |
| Cash & Short-term Investments | 43.3M | 254M | 383M | 302M | 567M | 51.7M | 9.39M |
| Total Debt | 532K | 1.88M | 4.83M | 4.34M | 2.46M | - | - |
| Cash Flow | |||||||
| Operating Cash Flow | -11.7M | -98.3M | -164M | -99.1M | 259M | 3.75M | 4.95M |
| Capital Expenditure | 0.00 | 888K | 948K | 1.84M | 375K | 2.00 | 1.00 |
| Free Cash Flow | -11.7M | -99.2M | -165M | -101M | 259M | 3.75M | 4.95M |
| Ratios | |||||||
| ROE | -62.2% | -64.5% | -55.6% | -42.4% | 53.5% | 3.9% | 23.9% |
| ROA | -55.5% | -50.1% | -46.1% | -34.4% | 50.3% | 3.9% | 23.9% |
| Debt to Equity | 0.01x | 0.01x | 0.01x | 0.02x | 0.00x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Debt to Equity
- Total debt divided by shareholders' equity.
LianBio dividends
- Dividend yield
- 886.05%
- Forward dividend
- -
- Payout ratio
- 964.8%
- Ex-dividend date
- Jul 15, 2025
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | USD 47.4M | 0.43 | 964.8% |
| 2024 | USD 551M | 5.07 | 22,239.2% |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns LianBio
- Insiders 0.00%
- Institutions 0.01%
- Public & others 99.99%
- Shares outstanding 109M
- Free float 108M
LianBio company profile
- Company name
- LianBio
- Ticker
- LIANY.US
- Exchange
- USA Stocks
- Listed since
- Nov 1, 2021
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 163
- Fiscal year end
- September
- Address
- 103 Carnegie Center Drive, Princeton, NJ, United States, 08540
- Phone
- 609 486 2308
- Website
- lian-medical.com/#
About LianBio
LianBio, operates as a biotechnology company in China and other Asian countries. It offers medicines for cardiovascular, oncology, ophthalmology, and inflammatory disease indications. The company develops mavacamten for the treatment of obstructive hypertrophic cardiomyopathy, which is in Phase 3 EXPLORER-CN trial; TP-03 for the treatment of Demodex blepharitis and meibomian gland disease, which is in Phase 3 LIBRA trial; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatment of FGFR2 gene amplification; and BBP-398 for solid tumors. The company was formerly known as LianBio and changed its name to LianMedical in July 2026. The company was incorporated in 2019 and is headquartered in Princeton, New Jersey.
LianBio management
6- Mr. Konstantin PoukalovFounder & Executive Chairman · born 1984
- Mr. Adam Leo StoneInterim CEO & Director · born 1980
- Ms. Ehong GuInterim CFO, VP & Head of Global Finance
- Ji ChenSenior VP & General Counsel
- Ms. Brianne PuglisiChief Business Officer · born 1987
- Dr. Levvy LvSenior VP & Global Head of Development